T2 diabetes mkt boom
August 8, 2016
NEW therapies coming on line
for the treatment of type 2 (T2)
diabetes will blow the market
out in South-East Asia from $1.7b
to $2.7b by 2022, a compound
annual growth rate (CAGR) of 7.1%,
according to business intelligence
provider GBI Research.
The region is expected to take up
these newer therapies in favour of
lower cost generics, the GBI report
said.
Six late-stage pipeline products
with the potential to “change the
treatment paradigm” stand out as
offering superior safety, efficacy,
and patient compliance.
They are comprised of two
offerings each from Novo Nordisk
and Merck as well as one each from
Eli Lilly and Theracos.
In spite of these trends, generic
metformin will remain the
mainstay of T2 diabetes therapy
both as the initial approach and in
combinations, GBI said.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Aug 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Aug 16